Regentis Biomaterials (RGNT) Debt to Equity (2024 - 2025)

Regentis Biomaterials (RGNT) reported Debt to Equity of $0.25 for Q4 2025, up 337.22% year-over-year from $0.06 in Q4 2024, and up 337.22% quarter-over-quarter from -$0.11 in Q4 2024.

Regentis Biomaterials (RGNT) Debt to Equity (2024 - 2025) Analysis & Trends

Regentis Biomaterials (RGNT) has 2 years of Debt to Equity data on file, last reported at $0.25 in Q4 2025.

  • Debt to Equity for Q4 2025 came in at $0.25, up 337.22% year-over-year; the trailing twelve-month figure through Dec 2025 was $0.25 (up 337.22% YoY), and the FY2025 annual result was $0.25, up 337.22% from the prior year.
  • Debt to Equity advanced to $0.25 in Q4 2025 per RGNT's latest filing, from -$0.11 in the prior quarter.
  • Over five years, Debt to Equity peaked at $0.25 in Q4 2025 and troughed at -$0.11 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Intuitive Surgical 148.09 Bn 143.69 Bn 1.83 Bn -
2 Becton Dickinson 41.00 Bn 39.99 Bn 2.15 Bn 0.72
3 Medline 30.38 Bn 36.22 Bn 1.84 Bn 1.12
4 Resmed 28.22 Bn 26.56 Bn 890.98 Mn 0.04
5 West Pharmaceutical Services 23.72 Bn 23.19 Bn 296.40 Mn 0.07
6 Solventum 13.33 Bn 13.33 Bn 1.10 Bn 1.02
7 Cooper Companies 13.12 Bn 12.99 Bn 735.40 Mn 0.30
8 Align Technology 12.86 Bn 11.80 Bn 736.59 Mn -
9 Baxter International 10.51 Bn 8.47 Bn 891.00 Mn 1.57
10 Regentis Biomaterials 3.72 Mn -3.66 Mn - 0.25

Historic Data

Download Data
DateValue
Dec 31, 2025 0.25
Dec 31, 2024 -0.11